Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy

Table 2

Characteristics of the different reviewed studies on mp-MRI for the diagnosis of local recurrence after RT.


Authors	MRI scan	Study design	Cases	Mean PSA	Reference standard	T2WI	DCE	MRSI	DWI	Combined techniques

Sala et al. [12]	PAC + ERC 1.5-T	Prospective	45	3.57 ng/dL	Whole-mount RP section	Se 36–76% Spe 65–81% 0.61–0.75

Westphalen et al. [13]	PAC + ERC 1.5-T	Retrospective	59		TRUS biopsy	Se 62–74% Sp 64–68% PPV 70–80% NPV 50–70% Acc 63–71%

Rouvière et al. [14]	PAC 1.5-T	Prospective	22	6.36 ng/dL	TRUS biopsy	Se 26–44% Sp 64–86% PPV 47–63% NPV 61–69% Acc 54–60%	Se 70–74% Sp 73–85% PPV 68–78% NPV 78-79% Acc 73–79%

Haider et al. [15]	PAC 1.5-T	Prospective	33	2.1 ng/dL	TRUS biopsy	Se 38% Sp 80% PPV 24% NPV 88% Acc 74%	Se 72% Sp 85% PPV 46% NPV 95% Acc 83%

Kara et al. [16]	PAC 1.5-T	Retrospective	20		TRUS biopsy	Se 86.7% Sp 100% PPV 100% NPV 71% Acc 90%	Se 93.3% Sp 100% PPV 100% NPV 83.3% Acc 95%

Menard et al. [17]		Prospective	35		TRUS biopsy			Se 88.9% Sp 92% PPV 91.7% Acc 91.4%

Coakley et al. [18]	PAC + ERC 1.5-T	Retrospective	21	2.3 ng/dL	TRUS biopsy	0.49–0.51		Se 89% Sp 82% PPV 64% NPV 96% 0.81

Pucar et al. [19]	PAC + ERC 1.5-T	Prospective	9	3.7 ng/dL	Whole-mount RP section	Se 68% Sp 96%		Se 77% Sp 78%

Westphalen et al. [20]	PAC + ERC 1.5-T	Retrospective	64	2.6 ng/dL	TRUS biopsy	0.67		T2WI + MRS: 0.79

Wu et al. [9]		Metanalysis				Se 74% Spe 65%	Se 90% Spe 81%			MRSI + DCE: Se 90% Spe 90%

Tamada et al. [21]	PAC 1.5-T	Retrospective	16	7.42 ng/dL	TRUS biopsy	Se 27% Sp 99% PPV 86% NPV 87% Acc 87%	Se 50% Sp 98% PPV 85% NPV 90% Acc 90%		Se 68% Sp 95% PPV 75% NPV 94% Acc 91%	T2WI + DCE + DWI: Se 77% Sp 92% PPV 68% NPV 95% Acc 90%

Kim et al. [22]	PAC 3.0-T	Prospective	36	3.44 ng/dL	TRUS biopsy	Se 25% Sp 92% PPV 57% NPV 74% 0.612				T2WI + DWI: Se 62% Sp 97% PPV 91% NPV 81% 0.879

Morgan et al. [23]	ERC 1.5-T	Retrospective	24		TRUS biopsy				Se 93.8% Sp 75% PPV 8.2% NPV 85.7%

Hara et al. [24]	PAC 1.5-T	Retrospective	10	4.44 ng/dL	TRUS biopsy				Se 69% Sp 91% PPV 37% NPV 97% Acc 89%

Arumainayagam et al. [25]	PAC 1.5-T	Retrospective	13		TRUS biopsy					T2WI + DCE + DWI: 0.86–0.93

Westphalen et al. [26]	PAC + ERC 3.0-T	Retrospective	26	2.5 ng/dL	TRUS biopsy	0.616		0.830	0.755	T2WI + MRS + DWI: 0.869 MRS + DWI: 0.863 T2WI + MRS: 0.841 T2WI + DWI: 0.774

Kim et al. [27]	PAC 3.0-T	Retrospective	24	2.76 ng/dL	TRUS biopsy	Se 27% Sp 80% PPV 32% NPV 76% Acc 67% 0.594	Se 49% Sp 92% PPV 67% NPV 84% Acc 81% 0.737		Se 49% Sp 93% PPV 72% NPV 84% Acc 82% 0.782	DCE + DWI: Se 59% Sp 91% PPV 69% NPV 87% Acc 83% 0.863

Akin et al. [28]	PAC + ERC 1.5-T	Retrospective	24	1.63 ng/dL	TRUS biopsy	Se 13–81% Sp 25–88% 0.53–0.64				T2WI + DCE + DWI: Se 81–94% Sp 75–100% 0.86–0.95

Donati et al. [29]	PAC + ERC 1.5 or 3.0-T	Retrospective	53		TRUS biopsy	Se 54–66% Sp 39–61% PPV 63–77% NPV 30–48% 0.46–0.632				T2WI + DCE: Se 60–63% Sp 56–89% PPV 73–91% NPV 44–53% 0.601–0.830 T2WI + DWI: Se 54–83% Sp 89–94% PPV 93–95% NPV 52–73% 0.812–0.863 T2WI + DCE + DWI: Se 49–71% Sp 94% PPV 94–96% NPV 49–63% 0.722–0.879

Roy et al. [11]	PAC + ERC 3.0-T	Retrospective	32	3.6 ng/dL	TRUS biopsy	Se 74%	Se 94%	Se 74%	Se 94%	T2WI + DCE: Se 91% T2WI + DWI + DCE: Se 100% T2WI + DWI + DCE + MRS: Se 76% T2WI + DWI: Se 94% T2WI + MRS: 44%

PAC: phased-array coil; ERC: endorectal coil; Se: sensitivity; Spe: specificity; PPV: positive predictive value; NPV: negative predictive value; Acc: accuracy; : area under the receiver operating curve.

BioMed Research International

Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy

Table 2